MRNA3771

**MRNA3771** is an investigational chronic hepatitis B therapeutic candidate attributed to nChroma Bio, but public-domain information is currently too limited to define it precisely beyond that association. Based on the naming convention and disease context, it appears to be an early-stage mRNA-based genetic medicine program for chronic hepatitis B; however, nChroma Bio's publicly described HBV lead program is **CRMA-1001**, a liver-targeted epigenetic editing therapy rather than a clearly described product named MRNA3771. Because I could not verify a distinct public description, mechanism, clinical stage, formulation, or exact modality for MRNA3771 itself, the entry should be treated as an incompletely characterized pipeline code pending confirmation from primary company materials.